Table 2.

Relative effect sizes for mean change in HbA_1c

Regimen	Change in HbA1c from baseline (%)
	Random effects model		Fixed effect model
	All vs. placebo Mean (95% CrI)	Exenatide QW vs. all Mean (95% CrI)	All vs. Placebo Mean (95% CrI)	Exenatide QW vs. all Mean (95% CrI)
Placebo	N/A	−1.09 (−1.65, −0.53)*	N/A	−1.19 (−1.52, −0.85)*
Dulaglutide 1.5 mg QW	−1.09 (−1.75, −0.43)*	0.00 (−0.72, 0.72)	−1.19 (−1.50, −0.87)*	0.00 (−0.33, 0.33)
Liraglutide 1.8 mg QD	−1.03 (−1.55, −0.51)*	−0.06 (−0.65, 0.54)	−1.13 (−1.41, −0.84)*	−0.06 (−0.36, 0.24)
Exenatide 10 µg BID	−0.75 (−1.11, −0.43)*	−0.34 (−0.95, 0.31)	−0.79 (−0.98, −0.61)*	−0.39 (−0.73, −0.06)*
Liraglutide 1.2 mg QD	−0.71 (−1.16, −0.26)*	−0.38 (−0.92, 0.16)	−0.81 (−1.07, −0.55)*	−0.38 (−0.66, −0.10)*
Albiglutide 30 mg QW	−0.69 (−1.11, −0.28)*	−0.39 (−1.00, 0.20)	−0.79 (−1.04, −0.55)*	−0.39 (−0.69, −0.10)*
Lixisenatide 20 µg QD	−0.50 (−0.75, −0.25)*	−0.59 (−1.15, −0.03)*	−0.62 (−0.81, −0.42)*	−0.57 (−0.89, −0.25)*
Exenatide 5 µg BID	−0.42 (−0.87, 0.00)*	−0.66 (−1.35, 0.05)	−0.40 (−0.65, −0.15)*	−0.79 (−1.20, −0.37)*
Exenatide 2 mg QW	−1.09 (−1.65, −0.53)*	N/A	−1.19 (−1.52, −0.85)*	N/A

BID twice daily, CrI credible interval, HbA1c glycated hemoglobin, N/A not applicable, QD once daily, QW once weekly

* Statistically significant difference